CN104530230A - 一种鸭甲肝病毒vp1蛋白基因及其应用 - Google Patents
一种鸭甲肝病毒vp1蛋白基因及其应用 Download PDFInfo
- Publication number
- CN104530230A CN104530230A CN201410775871.0A CN201410775871A CN104530230A CN 104530230 A CN104530230 A CN 104530230A CN 201410775871 A CN201410775871 A CN 201410775871A CN 104530230 A CN104530230 A CN 104530230A
- Authority
- CN
- China
- Prior art keywords
- virus
- duck hepatitis
- structural protein
- hav
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001651352 Avihepatovirus A Species 0.000 title claims abstract description 46
- 108700019200 hepatitis A virus VP1 Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 101710197658 Capsid protein VP1 Proteins 0.000 claims abstract description 35
- 241000894006 Bacteria Species 0.000 claims abstract description 21
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 21
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 19
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims abstract description 19
- 101710108545 Viral protein 1 Proteins 0.000 claims abstract description 19
- 101710106388 Structural protein VP1 Proteins 0.000 claims abstract description 16
- 239000000427 antigen Substances 0.000 claims abstract description 8
- 108091007433 antigens Proteins 0.000 claims abstract description 8
- 102000036639 antigens Human genes 0.000 claims abstract description 8
- 239000013604 expression vector Substances 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 5
- 241000709721 Hepatovirus A Species 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 241001557656 Duck hepatitis A virus 1 Species 0.000 abstract description 21
- 241001557661 Duck hepatitis A virus 3 Species 0.000 abstract description 21
- 239000002131 composite material Substances 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 9
- 238000002649 immunization Methods 0.000 abstract description 5
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 abstract description 3
- 238000004458 analytical method Methods 0.000 abstract description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 abstract 3
- 241000272522 Anas Species 0.000 abstract 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 description 19
- 241000272525 Anas platyrhynchos Species 0.000 description 16
- 239000007788 liquid Substances 0.000 description 12
- 235000013601 eggs Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000011330 nucleic acid test Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000007689 inspection Methods 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 238000004321 preservation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101150024766 VP1 gene Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000011265 semifinished product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 238000004500 asepsis Methods 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000001357 Cystobacterineae bacterium Species 0.000 description 1
- 241001557655 Duck hepatitis A virus 2 Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000239222 Tachypleus Species 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009654 indole test Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108010046845 tryptones Proteins 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229930195727 α-lactose Natural products 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410775871.0A CN104530230B (zh) | 2014-12-13 | 2014-12-13 | 一种鸭甲肝病毒vp1蛋白基因及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410775871.0A CN104530230B (zh) | 2014-12-13 | 2014-12-13 | 一种鸭甲肝病毒vp1蛋白基因及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104530230A true CN104530230A (zh) | 2015-04-22 |
CN104530230B CN104530230B (zh) | 2018-01-30 |
Family
ID=52845890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410775871.0A Expired - Fee Related CN104530230B (zh) | 2014-12-13 | 2014-12-13 | 一种鸭甲肝病毒vp1蛋白基因及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104530230B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105754959A (zh) * | 2016-03-13 | 2016-07-13 | 山东省农业科学院家禽研究所(山东省无特定病原鸡研究中心) | 表达dhav-1和dhav-3型vp1基因的ndv重组病毒及其应用 |
CN106924725A (zh) * | 2017-03-16 | 2017-07-07 | 中国水产科学研究院珠江水产研究所 | 一种弧菌外膜蛋白亚单位佐剂疫苗及规模化制备技术 |
CN111454337A (zh) * | 2020-03-04 | 2020-07-28 | 山东农业大学 | 1型和3型鸭甲肝病毒共有的中和性模拟抗原表位及其应用 |
CN117069866A (zh) * | 2023-10-16 | 2023-11-17 | 东北农业大学 | 一种鸭甲型肝炎病毒3型重组免疫原及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948809A (zh) * | 2010-08-06 | 2011-01-19 | 中国科学院微生物研究所 | 预防鸭病毒性肝炎的灭活疫苗及其制备方法 |
CN104087609A (zh) * | 2014-07-10 | 2014-10-08 | 山东省农业科学院家禽研究所 | 一种通用型鸭甲型肝炎病毒抗体elisa检测试剂盒 |
-
2014
- 2014-12-13 CN CN201410775871.0A patent/CN104530230B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948809A (zh) * | 2010-08-06 | 2011-01-19 | 中国科学院微生物研究所 | 预防鸭病毒性肝炎的灭活疫苗及其制备方法 |
CN104087609A (zh) * | 2014-07-10 | 2014-10-08 | 山东省农业科学院家禽研究所 | 一种通用型鸭甲型肝炎病毒抗体elisa检测试剂盒 |
Non-Patent Citations (4)
Title |
---|
LU J.,ET AL.: "ACCESSION NO:ADB77881.1,VP1 [Duck hepatitis A virus 1]", 《GENBANK DATABASE》 * |
MIN-CHUL KIM,ET AL.: "Development of duck hepatitis A virus type 3 vaccine and its use to protect ducklings against infections", 《VACCINE》 * |
WANG C.,ET AL.: "ACCESSION NO:ABX84366.1,VP1 [Duck hepatitis A virus 3]", 《GENBANK DATABASE》 * |
李传峰等: "鸭甲型肝炎病毒衣壳蛋白B细胞抗原表位和密码子偏爱性的分析", 《中国兽医科学》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105754959A (zh) * | 2016-03-13 | 2016-07-13 | 山东省农业科学院家禽研究所(山东省无特定病原鸡研究中心) | 表达dhav-1和dhav-3型vp1基因的ndv重组病毒及其应用 |
CN105754959B (zh) * | 2016-03-13 | 2019-05-31 | 山东省农业科学院家禽研究所(山东省无特定病原鸡研究中心) | 表达dhav-1和dhav-3型vp1基因的ndv重组病毒及其应用 |
CN106924725A (zh) * | 2017-03-16 | 2017-07-07 | 中国水产科学研究院珠江水产研究所 | 一种弧菌外膜蛋白亚单位佐剂疫苗及规模化制备技术 |
CN111454337A (zh) * | 2020-03-04 | 2020-07-28 | 山东农业大学 | 1型和3型鸭甲肝病毒共有的中和性模拟抗原表位及其应用 |
CN111454337B (zh) * | 2020-03-04 | 2021-08-13 | 山东农业大学 | 1型和3型鸭甲肝病毒共有的中和性模拟抗原表位及其应用 |
CN117069866A (zh) * | 2023-10-16 | 2023-11-17 | 东北农业大学 | 一种鸭甲型肝炎病毒3型重组免疫原及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104530230B (zh) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103451196A (zh) | 密码子优化的猪圆环病毒2型Cap蛋白编码基因及其应用 | |
CN106519041A (zh) | 猪免疫球蛋白Fc片段和猪瘟E2融合蛋白在CHO细胞株的构建方法及其制备方法和应用 | |
CN104530230B (zh) | 一种鸭甲肝病毒vp1蛋白基因及其应用 | |
CN104498441A (zh) | 鸭甲肝病毒iii型弱毒株及由其制备的活疫苗和应用 | |
CN104031874A (zh) | 一种双基因缺失粗糙型牛种布鲁氏菌及其疫苗的生产方法 | |
CN104448005B (zh) | 鸭甲肝病毒3型vp1蛋白和ltb的融合蛋白抗原及其应用 | |
CN102181457B (zh) | 密码子优化的艰难梭菌外毒素b氨基端基因序列及其核酸疫苗 | |
CN104610455B (zh) | 一种鸭坦布苏病毒基因工程亚单位疫苗 | |
CN103540605A (zh) | 重组ⅱ型猪圆环病毒的衣壳蛋白噬菌体展示颗粒及其制备方法与应用 | |
CN101979502B (zh) | 表达o型口蹄疫病毒vp1基因的重组布鲁氏菌及其疫苗的生产方法 | |
CN111925426B (zh) | 一种产气荚膜梭菌α毒素突变体、表达系统、制备方法及应用 | |
CN110124025A (zh) | 一种禽流感与禽腺病毒4型二联基因工程亚单位疫苗及其制备方法 | |
CN104328135B (zh) | 鸭坦布苏病毒e蛋白和ltb的融合蛋白及其应用 | |
CN104004697A (zh) | 一种单基因缺失粗糙型布鲁氏菌及其疫苗的生产方法 | |
CN103626878B (zh) | 鸡新城疫病毒f蛋白和肠毒素ltb的融合蛋白及应用 | |
CN103830722A (zh) | 一种产气荚膜梭菌β毒素基因工程疫苗及其应用 | |
CN105754905A (zh) | 一种水貂绿脓杆菌及其应用 | |
CN102993310B (zh) | 鸡ibd病毒vp2和鸡il-2的融合蛋白及其应用 | |
CN111961121B (zh) | 产气荚膜梭菌ε毒素突变体蛋白及其制备方法、应用和疫苗 | |
CN104372013B (zh) | 一种鸭甲肝病毒基因工程亚单位疫苗 | |
CN111454336B (zh) | 一种改造的鸭圆环病毒Cap蛋白及其制备方法和应用 | |
CN104861048B (zh) | 鲍曼不动杆菌假定蛋白a1s_1462蛋白及制备方法和应用 | |
CN107164252A (zh) | 一种rhdv的亚单位疫苗 | |
CN105833263A (zh) | 一种禽偏肺病毒和h9亚型禽流感病毒二联疫苗 | |
CN103585622A (zh) | 猪支原体肺炎疫苗株的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170719 Address after: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Applicant after: Guangdong Gaohang Intellectual Property Operation Co., Ltd. Address before: Chengyang District of Shandong city in Qingdao province 266109 Xifu Cianjin King Road on the north side of the community Applicant before: QINGDAO HONGHAO BIOLOGICAL TECHNOLOGY CO., LTD. |
|
CB03 | Change of inventor or designer information |
Inventor after: Zhuang Hongzhang Inventor before: Wang Honghua |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171215 Address after: 362100 Quanzhou City, Fujian Province, Huian City, screw Town, building, floor two, floor 16 Applicant after: Huian Yicheng electromechanical equipment Engineering Co., Ltd. Address before: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Applicant before: Guangdong Gaohang Intellectual Property Operation Co., Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200709 Address after: 226000 No.40, Zhonghua East Road, Sanchang street, Haimen City, Nantong City, Jiangsu Province Patentee after: NANTONG JUJIU NEW MATERIAL TECHNOLOGY Co.,Ltd. Address before: 362100 Quanzhou City, Fujian Province, Huian City, screw Town, building, floor two, floor 16 Patentee before: HUI'AN YICHENG ELECTROMECHANICAL EQUIPMENT ENGINEERING Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201111 Address after: Room 207, 2 / F, building 5, No. 688, Bin'an Road, Changhe street, Binjiang District, Hangzhou City, Zhejiang Province Patentee after: Hangzhou Baiyu Biotechnology Co., Ltd Address before: 226000 No.40, Zhonghua East Road, Sanchang street, Haimen City, Nantong City, Jiangsu Province Patentee before: NANTONG JUJIU NEW MATERIAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180130 Termination date: 20201213 |
|
CF01 | Termination of patent right due to non-payment of annual fee |